Gammapatía monoclonal de significado incierto

1.Landgren O , Kyle RA , Pfeiffer RM et al . Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study . Blood 2009; 113 : 5412 – 7 .

2 International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma . http://imwg.myeloma. org/ internationalmyeloma-working-group-imwg-criteria-for-thediagnosis- of-multiplemyeloma/ [ Accessed 30 July 2018 ].

3 Bird J , Owen R , D'Sa S et al. Guidelines for the diagnosis and management of multiple myeloma 2014 . London : British Society for Haematology, 2015.

4 Kristinsson SY , Bjorkholm M , Andersson TM et al . Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study . Haematologica 2009; 94: 1714 – 20.

5 Kyle RA , Durie BG , Rajkumar SV et al . Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management . Leukemia 2010; 24 : 1121 – 7.

6 van de Donk NW , Palumbo A , Johnsen HE et al . The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network . Haematologica 2014 ; 99 : 984 – 96 .

7 Landgren O , Gridley G , Turesson I et al . Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States . Blood 2006 ; 107 : 904 – 6 .

8 Kaufmann H , Ackermann J , Baldia C et al . Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma . Leukemia 2004 ; 18 : 1879 .

9 Hoyer JD , Hanson CA , Fonseca R et al . The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study . Am J Clin Pathol 2000; 113: 831– 7.

10 Yang K , Hitomi M , Stacey DW . Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell . Cell Div 2006 ; 1 : 32 .

11 Bergsagel PL , Kuehl WM , Zhan F et al . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma . Blood 2005; 106 : 296 – 303.

12 Walker BA , Wardell CP , Melchor L et al . Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms . Leukemia 2014; 28: 384 – 90.

13 Bird J , Behrens J , Westin J et al . UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) . Br J Haematol 2009; 147 : 22 – 42.

14 Kristinsson SY , Tang M , Pfeiffer RM et al . Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study . Blood 2010 ; 116 : 2651 – 5.

15 Vejlgaard T , Abildgaard N , Jans H , Nielsen JL , Heickendorff L. Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens . Eur J Haematol 1997; 58 : 104 – 8 .

16 Pecherstorfer M , Seibel MJ , Woitge HW et al. Bone resorption in  multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen . Blood 1997 ; 90 : 3743 – 50 .

17 Politou M , Terpos E , Anagnostopoulos A et al . Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS) . Br J Haematol 2004; 126: 686– 9.

18 Kurihara N , Bertolini D , Suda T , Akiyama Y , Roodman GD . IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release . J Immunol 1990 ; 144 : 4226 – 30 .

19 Bida JP , Kyle RA , Therneau T et al . Disease associations with monoclonal gammopathy of undetermined significance: a population based study of 17,398 patients . Mayo Clin Proc 2009; 84: 685– 93.

20 Berenson JR , Yellin O , Boccia RV et al . Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss . Clin Cancer Res 2008 ; 14 : 6289 – 95 .

21 Gregersen H , Madsen K , Sorensen H . The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol 1998; 61: 140– 4.

22 Karlsson J , Hogevik H , Andersson K et al . Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Trials Vaccinol 2013; 2( Suppl C): 31– 8.

23 Karlsson J , Andreasson B , Kondori N et al . Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol 2011 ; 18 : 969 – 77 .

24 Pozzi C , D’Amico M , Fogazzi GB , Curioni S , Ferrario F , Pasquali S et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors . Am J Kidney Dis 42 : 1154 –63 .

25 Heilman RL , Velosa JA , Holley KE , Offord KP , Kyle RA . Longterm follow-up and response to chemotherapy in patients with lightchain deposition disease . Am J Kidney Dis 1992 ; 20 : 34 – 41 .

26 Lin J , Markowitz GS , Valeri AM et al . Renal monoclonal immunoglobulin deposition disease: the disease spectrum . J Am Soc Nephrol 2001 ; 12 : 1482 – 92 .

27 Nasr SH , Satoskar A , Markowitz GS et al . Proliferative glomerulonephritis with monoclonal IgG deposits . J Am Soc Nephrol 2009 ; 20 : 2055 – 64 .

28 Kapur U , Barton K , Fresco R , Leehey DJ , Picken MM . Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy . Arch Pathol Lab Med 2007 ; 131 : 1368 – 72 .

29 Lunn M , Nobile-Orazio E . Immunotherapy for IgM antimyelinassociated glycoprotein paraprotein-associated peripheral neuropathies . Cochrane Database Syst Rev 2016 ; 10 : CD002827 .

30 Campagnolo M , Ferrari S , Dalla Torre C et al . Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment . J Neuroimmunol 2015 ; 281 : 1 – 4 .

31 Kristinsson SY , Pfeiffer RM , Bjorkholm M et al . Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010 ; 115 : 4991 – 8 .